PSTX News and Press, Poseida Therapeutics Inc.

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...

2024-05-30 08:15:34 ET Summary Poseida Therapeutics is a biopharmaceutical company specializing in cell and gene therapies for cancer and genetic conditions. The company's proprietary gene editing and delivery platforms show potential for partnerships and future research agreement...

2024-05-14 17:07:19 ET More on Poseida Therapeutics Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement Poseida gains on cell therapy pact with Astellas Poseida spikes after FDA orphan status for CAR-T therapy Seeking Alpha’s ...

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting PR Newswire Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...

2024-05-01 14:28:11 ET A California-based %Biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary. Shares of %PoseidaTherapeutics (Nasdaq: $P...

2024-05-01 13:54:38 ET Poseida Therapeutics ( NASDAQ: PSTX ) shares traded higher on Wednesday after the company and Japanese drugmaker Astellas ( OTCPK:ALPMY ) announced a partnership to develop and commercialize CAR-T cell therapies for cancer.... Read the full article o...

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting PR Newswire Company to deliver three oral and three poster presentations highlighting its portfolio of non-viral genetic medicines Present...